AIM To study the
pharmacokinetics of a new radiosensitizing agent
glycididazolum natrium (CMNa) in lung cancer patients
after single and multiple dose administration. METHODS Twenty four cancer patients were for single dose study; and 5 patients were for multiple dose study. The CMNa and metronidazole concentrations in blood and urine were determined by HPLC with UV detector. The blood CMNa concentration time curves were simulated by 3P97 software and the pharmacokinetic parameters were calculated. RESULTS The blood CMNa concentration time curves in single dose groups were fitted to two compartment open model , t 1/2β were 0.76-2.62 h ,c max were 13.31-43.90 mg·L -1 , AUC were 8.68-29.94 mg·h·L -1 in 400, 500, 600, 700, 800 and 900 mg·m -2 dose groups, respectively and their c max and AUC were direct proportional to doses. The blood concentration time curves,
pharmacokinetics parameters, and excretion ratios between single dose and multiple dose were similar, and there was no significant difference. CONCLUSION CMNa distributed and eliminated rapidly, so CMNa will not accumulate in patients′ bodies if it is administered at an appropriate interval.